Wall Street is positive on SAGE Therapeutics Inc (SAGE). On average, analysts give SAGE a buy rating. The average price target is $ 77.368, which means analysts expect the stock to rise 82.47% over the next twelve months. This average ranking gives SAGE an analyst rating of 27, which is better than 27% of stocks based on data compiled by Investors Observer.
Why are analyst ratings important?
A company’s financial statements are an important factor weighted by experts when analyzing the health of a business. Beyond the numbers, analysts follow specific sectors closely and are able to understand in detail how a storm in one part of the world can shut down supply chains, causing consumption to shift across the globe. This knowledge allows investors to react to potential market changes before they are revealed in a quarterly announcement.
Investors Observer averages the scores of all these analysts and ranks those averages into percentiles. This allows you to compare stocks in more detail than the usual five-tier system used by the majority of investors.
What is happening with the shares of SAGE Therapeutics Inc today?
SAGE Therapeutics Inc (SAGE) stock is 5.05% higher while the S&P 500 fell -0.14% at 10:56 a.m. on Monday, November 1. SAGE was up $ 2.04 from the previous closing price of $ 40.36 on volume of 124,131 shares. Over the past year, the S&P 500 has risen 38.93% while the SAGE has fallen -40.85%. SAGE has earned $ 11.84 per share over the past 12 months, giving it a price-to-earnings ratio of 3.58. Click here for the full report on SAGE Therapeutics Inc.